These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9375737)

  • 1. Sickle cell disease: relation between procoagulant activity of red blood cells from different phenotypes and in vivo blood coagulation activation.
    Helley D; Girot R; Guillin MC; Bezeaud A
    Br J Haematol; 1997 Nov; 99(2):268-72. PubMed ID: 9375737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.
    Whelihan MF; Lim MY; Mooberry MJ; Piegore MG; Ilich A; Wogu A; Cai J; Monroe DM; Ataga KI; Mann KG; Key NS
    J Thromb Haemost; 2016 Oct; 14(10):1941-1952. PubMed ID: 27430959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassemia.
    Helley D; Eldor A; Girot R; Ducrocq R; Guillin MC; Bezeaud A
    Thromb Haemost; 1996 Sep; 76(3):322-7. PubMed ID: 8883264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombophilia in sickle cell disease: the red cell connection.
    Setty BN; Rao AK; Stuart MJ
    Blood; 2001 Dec; 98(12):3228-33. PubMed ID: 11719358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced thrombin generation in children with sickle cell disease.
    Peters M; Plaat BE; ten Cate H; Wolters HJ; Weening RS; Brandjes DP
    Thromb Haemost; 1994 Feb; 71(2):169-72. PubMed ID: 8191393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulation changes in individuals with sickle cell trait.
    Westerman MP; Green D; Gilman-Sachs A; Beaman K; Freels S; Boggio L; Allen S; Schlegel R; Williamson P
    Am J Hematol; 2002 Feb; 69(2):89-94. PubMed ID: 11835343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation.
    Setty BN; Kulkarni S; Rao AK; Stuart MJ
    Blood; 2000 Aug; 96(3):1119-24. PubMed ID: 10910931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Chronic Blood Transfusion on Biomarkers of Coagulation Activation and Thrombin Generation in Sickle Cell Patients at Risk for Stroke.
    Hyacinth HI; Adams RJ; Greenberg CS; Voeks JH; Hill A; Hibbert JM; Gee BE
    PLoS One; 2015; 10(8):e0134193. PubMed ID: 26305570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Red blood cells from patients with homozygous sickle cell disease provide a catalytic surface for factor Va inactivation by activated protein C.
    Bezeaud A; Venisse L; Helley D; Trichet C; Girot R; Guillin MC
    Br J Haematol; 2002 May; 117(2):409-13. PubMed ID: 11972526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the procoagulant activity of endogenous phospholipids in the platelet-free plasma of children with sickle cell disease using functional assays.
    Noubouossie DC; Lê PQ; Rozen L; Debaugnies F; Ferster A; Demulder A
    Thromb Res; 2012 Aug; 130(2):259-64. PubMed ID: 22079446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational imaging analysis of fibrin matrices with the inclusion of erythrocytes from homozygous SS blood reveals agglomerated and amorphous structures.
    Averett RD; Norton DG; Fan NK; Platt MO
    J Thromb Thrombolysis; 2017 Jan; 43(1):43-51. PubMed ID: 27664114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Red blood cells may contribute to hypercoagulability in uraemia via enhanced surface exposure of phosphatidylserine.
    Bonomini M; Sirolli V; Merciaro G; Antidormi T; Di Liberato L; Brummer U; Papponetti M; Cappelli P; Di Gregorio P; Arduini A
    Nephrol Dial Transplant; 2005 Feb; 20(2):361-6. PubMed ID: 15598665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients.
    Atichartakarn V; Angchaisuksiri P; Aryurachai K; Onpun S; Chuncharunee S; Thakkinstian A; Atamasirikul K
    Br J Haematol; 2002 Sep; 118(3):893-8. PubMed ID: 12181063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo.
    Head CA; Brugnara C; Martinez-Ruiz R; Kacmarek RM; Bridges KR; Kuter D; Bloch KD; Zapol WM
    J Clin Invest; 1997 Sep; 100(5):1193-8. PubMed ID: 9276736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human endothelial cells suppress prothrombin activation in nonanticoagulated whole blood in vitro.
    Biedermann B; Rosenmund A; Muller M; Kohler HP; Haeberli A; Straub PW
    J Lab Clin Med; 1994 Sep; 124(3):339-47. PubMed ID: 8083577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of factor Xa in determining the procoagulant activity of whole-blood clots.
    Eisenberg PR; Siegel JE; Abendschein DR; Miletich JP
    J Clin Invest; 1993 May; 91(5):1877-83. PubMed ID: 8486759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypercoagulable state in sickle cell disease.
    Faes C; Sparkenbaugh EM; Pawlinski R
    Clin Hemorheol Microcirc; 2018; 68(2-3):301-318. PubMed ID: 29614638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo evaluation of the effect of sickle cell hemoglobin S, C and therapeutic transfusion on erythrocyte metabolism and cardiorenal dysfunction.
    D'Alessandro A; Nouraie SM; Zhang Y; Cendali F; Gamboni F; Reisz JA; Zhang X; Bartsch KW; Galbraith MD; Gordeuk VR; Gladwin MT
    Am J Hematol; 2023 Jul; 98(7):1017-1028. PubMed ID: 36971592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations among sickle cell disease patients of Central India.
    Nishank SS; Singh MP; Yadav R
    Eur J Haematol; 2013 Nov; 91(5):462-6. PubMed ID: 23992124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients.
    Kurantsin-Mills J; Ofosu FA; Safa TK; Siegel RS; Lessin LS
    Br J Haematol; 1992 Aug; 81(4):539-44. PubMed ID: 1390242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.